Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)
All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be
Observational Model: Case-Only, Time Perspective: Prospective
Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane
Assessment of factors likely to affect the safety and/or efficacy: reason for Exemestane use (primary progressive breast cancer, relapsed breast cancer or postoperative adjuvant therapy)and past history (presence or absence of at least one disease).
Pfizer CT.gov Call Center
Japan: Pharmaceuticals and Medical Devices Agency